UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 8 von 529
Datensatz exportieren als...
BibTeX
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
Movement disorders, 2005-08, Vol.20 (8), p.932-936
Bara-Jimenez, William
Bibbiani, Francesco
Morris, Michael J.
Dimitrova, Tzvetelina
Sherzai, Abdullah
Mouradian, Maral M.
Chase, Thomas N.
2005
Details
Autor(en) / Beteiligte
Bara-Jimenez, William
Bibbiani, Francesco
Morris, Michael J.
Dimitrova, Tzvetelina
Sherzai, Abdullah
Mouradian, Maral M.
Chase, Thomas N.
Titel
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
Ist Teil von
Movement disorders, 2005-08, Vol.20 (8), p.932-936
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2005
Link zum Volltext
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5‐HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5‐HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3‐week, double‐blind, placebo‐controlled, proof‐of‐concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa‐induced dyskinesias and prolonged its antiparkinsonian response (P ≤ 0.05). Under the conditions of this study, our findings suggest that 5‐HT1A receptor stimulation in levodopa‐treated parkinsonian patients can modulate striatal dopaminergic function and that 5‐HT1A agonists may be useful as levodopa adjuvants in the treatment of PD. © 2005 Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.20370
Titel-ID: cdi_proquest_miscellaneous_68446918
Format
–
Schlagworte
5-HT1A receptor
,
Aged
,
Antiparkinson Agents - therapeutic use
,
Biological and medical sciences
,
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
,
dopamine
,
Dose-Response Relationship, Drug
,
Double-Blind Method
,
Drug Evaluation - methods
,
dyskinesias
,
dyskinesias, levodopa
,
Female
,
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
,
Humans
,
levodopa
,
Male
,
Medical sciences
,
Middle Aged
,
Nervous system (semeiology, syndromes)
,
Neurology
,
Organic Chemicals
,
Parkinson Disease - drug therapy
,
Parkinson's disease
,
serotonin
,
Serotonin 5-HT1 Receptor Agonists
,
Severity of Illness Index
,
striatum
,
Treatment Outcome
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX